<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548612</url>
  </required_header>
  <id_info>
    <org_study_id>SNPSCZ001</org_study_id>
    <nct_id>NCT01548612</nct_id>
  </id_info>
  <brief_title>Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia</brief_title>
  <official_title>Randomised Double Blind Placebo Controlled Study of Sodium Nitroprusside Added to Treatment as Usual in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In spite of the numerous studies on schizophrenia, its etiology and physiopathology remain
      unknown. Evidence suggests a possible implication of nitric oxide (NO) in schizophrenia. NO
      is a gas with unique chemistry and influences the release of neurotransmitters, learning,
      memory and neurodevelopment. Recent studies that investigated the role of NO in patients with
      schizophrenia found evidence that points to a disruption in NO-mediated neurotransmission in
      schizophrenia. Accordingly, we believe that the administration of sodium nitroprusside, an NO
      donor, will ameliorate schizophrenia symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BPRS score</measure>
    <time_frame>baseline and up to 4 weeks</time_frame>
    <description>Brief Psychiatric Rating Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PANSS negative subscale score</measure>
    <time_frame>Every hour for 4 hours, then at +12h, then daily for 7 days, then weekly for 4 weeks</time_frame>
    <description>Positive and Negative Syndrome Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive assessment</measure>
    <time_frame>Baseline and after 12 h</time_frame>
    <description>FAS, 2-back, Stroop Color Word Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Sodium nitroprusside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glucose solution 5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitroprusside</intervention_name>
    <description>Intravenous infusion of 0,5 mcg/kg/min for 240 minutes</description>
    <arm_group_label>Sodium nitroprusside</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose solution</intervention_name>
    <description>Intravenous infusion of glucose solution 5% for 240 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia

          -  Patients in an acute psychotic episode requiring full hospitalization

        Exclusion Criteria:

          -  Significant medical conditions (heart, kidney, liver, thyroid or neurological
             diseases, hypovitaminosis B12, hyponatremia)

          -  Pregnancy

          -  Breastfeeding

          -  Previous hypersensitivity to sodium nitroprusside

          -  DSM-IV diagnosis of drug abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime EC Hallak, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ribeirao Preto Medical School, University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital of the Ribeirao Preto Medical School</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Jaime Eduardo Cecilio Hallak</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>Sodium nitroprusside</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

